For the quarter ending 2026-03-31, IGC made $317K in revenue. -$2,410K in net income. Net profit margin of -760.25%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 317 | 91* | 191 | 328 |
| Cost of revenue | 262 | 173* | 92 | 174 |
| Selling, general, and administrative expenses | 1,241 | 194* | 1,410 | 1,208 |
| Research and development expenses | 1,272 | 263* | 1,588 | 851 |
| Operating loss | -2,458 | -539* | -2,899 | -1,905 |
| Other income, net | 56 | 1,523* | 1,078 | 306 |
| Gain before income taxes | -2,402 | 984* | -1,821 | -1,599 |
| Income tax expense/benefit | 0 | 0* | 0 | 0 |
| Net gain attributable to common stockholders | -2,402 | 984* | -1,821 | -1,599 |
| Foreign currency translation adjustments | -8 | -7* | -19 | -3 |
| Comprehensive gain | -2,410 | 977 | -1,840 | -1,602 |
| Basic EPS | -0.02 | 0.01 | -0.02 | -0.02 |
| Diluted EPS | -0.02 | 0.01 | -0.02 | -0.02 |
| Basic Average Shares | 98,161,733 | 93,069,641 | 90,457,910 | 83,027,117 |
| Diluted Average Shares | 98,161,733 | 93,069,641 | 90,457,910 | 83,027,117 |
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)